Johnson & Johnson has received a boost in its ongoing tussle for the top spot in the drug-eluting stent market after it prevailed in three long-standing lawsuits involving rival Boston Scientific. Boston was ordered to pay J&J a settlement fee of $1.73bn to resolve three ...
Please Login to read the full article.
